6021-31-4

Usage

Uses

Used in Pharmaceutical Industry:
4-hydroxy-2,3-dimethyl-benzoic acid is used as an intermediate for the synthesis of various drugs, contributing to the development of new medications.
Used in Cosmetic and Personal Care Industry:
4-hydroxy-2,3-dimethyl-benzoic acid is used as a preservative in cosmetic and personal care products, thanks to its antioxidant properties, which help maintain the quality and shelf life of these products.
Used in Food Industry:
4-hydroxy-2,3-dimethyl-benzoic acid is used as a preservative in food packaging materials, ensuring the freshness and safety of packaged foods.

Upstream product

• 5628-44-4 amyldimethyl-para-aminobenzoic acid 
• 5628-61-5 4-methoxy-2,3-dimethyl-benzoic acid 
• 38998-17-3 2,3-dimethyl-4-methoxybenzaldehyde 
• 52962-97-7 2,3-dimethyl-4-nitrobenzonitrile 
• 90557-85-0 4-Nitro-2,3-dimethyl-benzamid 
• 90564-15-1 4-Nitro-2,3-dimethyl-benzoesaeure 
• 80879-86-3 2,3-dimethyl-4-nitroaniline 
• 134-98-5 N-(2,3-dimethylphenyl)acetamide 

Downstream Products

• 5628-61-5 4-methoxy-2,3-dimethyl-benzoic acid 
• 5628-56-8 methyl 2,3-dimethyl-4-hydroxybenzene-1-carboxylate 
• 148581-24-2 4-benzyloxy-2,3-dimethylbenzoic acid 
• 148581-22-0 4-Benzyloxy-2,3-dimethyl-benzoyl chloride 
• 148254-93-7 2,3-dimethyl-4-<1-(4-isobutylphenyl)ethoxy>benzoic acid 
• 187675-70-3 4-[2-(4-Hydroxy-2,3-dimethyl-benzoylamino)-phenoxy]-butyric acid ethyl ester 

Relevant academic research and scientific papers

CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.

Steroid 5α-reductase: Comparative study of mechanism of inhibition by nonsteroids ONO-3805 and LY191704

Two nonsteroids, ONO-3805 and LY191704, were evaluated as inhibitors of the human and rat 5α-reductases (5αR). ONO-3805 was prepared in a 12-step convergent synthesis. This compound is a potent inhibitor of the human and rat 5αRs, with more potent inhibition seen against the rat enzymes. The inhibition patterns of this compound were best fit to an uncompetitive model which suggests binding in a ternary complex with enzyme and NADP+. Apparent K(i) values of 27, 31, 1, and 0.5 nM versus testosterone were obtained with human type 1, human type 2, rat type 1, and rat type 2 5αR, respectively. Multiple inhibition studies with ONO-3805 and NADP+ support synergistic binding of these two inhibitors with all isozymes. LY191704 was also evaluated as an inhibitor of the human and rat 5αRs. This compound is a selective, competitive inhibitor of human type 1 5αR. Poor inhibition was observed with human type 2 and rat types 1 and 2 5αR.